학술논문

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
Document Type
Article
Source
The Lancet Respiratory Medicine; April 2024, Vol. 12 Issue: 4 pe21-e30, 10p
Subject
Language
ISSN
22132600; 22132619
Abstract
Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.